For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

Now, although the funding environment looks different from the pandemic-era biotech bubble, conditions are ripening for the return of the IPO as a viable exit for private drugmakers, according to a ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

Discover what were the top biotech deals that were signed in March 2026. From small molecules to antibodies, M&A activity was high.

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from ...

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...